PHIO
Phio Pharmaceuticals Corp.Company with tickers: PHIO
CIK
1533040
CUSIP
71880W501
Shares Outstanding
11,617,250
Website
https://www.phiopharma.com
Investor Relations
https://phiopharma.com/investors/
13F Activity (30d)
2 filings
1 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $4,167,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Research & Development | $2,793,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-4,167,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-4,003,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $-0.34 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | — |